← All trials
NCT06377852
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 29, 2024
- Primary completion
- Aug 31, 2028
- Completion date
- Sep 1, 2028
- First posted
- Apr 22, 2024
- Last posted
- Nov 6, 2024
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- American Society of Clinical OncologyLead sponsor
- American Society of Clinical OncologyOfficial
- Patient-Centered Outcomes Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.